- Trial Phase
- Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2))
- Time to Market
- Already marketed — FDA approved March 21, 2025; US commercial launch announced June 2025
- Why 3/10
- No hard, dated binary remains for Gozellix in the next ~12 months — its FDA approval (the defining catalyst) passed on March 21, 2025 and the drug is already commercially launched, so the share-price story now hinges on gradual revenue ramp and Telix's separate therapy-pipeline readouts (e.g., ProstACT), not on Gozellix itself; per the rubric an approved, marketed drug with no pending regulatory decision scores 3-5, and Gozellix is one of two imaging products at a company with bigger pipeline catalysts, so 3.
Gozellix is an already-approved, launched product, so there is no approval binary left to trade — the investor angle is commercial execution. Watch Telix's quarterly revenue disclosures (FY2026 guidance of ~US$950-970M plus US$40M Regeneron other income, Q2 2026 reported Aug 20, 2026) and any market-share data vs. Lantheus' PYLARIFY and Telix's own Illuccix, since Gozellix partly cannibalizes its sibling product. Bigger single-stock moves in TLX over the next year are more likely to come from the therapy pipeline (ProstACT Phase 3) than from this imaging agent.
Price Chart
Executive Summary
Gozellix (TLX007-CDx) is Telix Pharmaceuticals' second-generation PSMA-PET imaging agent for prostate cancer — a kit for preparing gallium-68 gozetotide injection — approved by the FDA on March 21, 2025 under a 505(b)(2) NDA and launched in the US in June 2025. It is a commercial success so far: Telix hit upgraded FY2025 revenue guidance of ~US$804M (Q4 up 46% YoY, partly driven by the Gozellix launch) and H1 2026 Precision Medicine revenue rose 27% YoY on the two-product Illuccix/Gozellix strategy. The stock trades around US$12.12 (Nasdaq: TLX) with analyst price targets implying meaningful upside, but Gozellix's defining binary has passed and the next major TLX catalysts belong to Telix's therapy pipeline, not this diagnostic.
How It Works
A diagnostic imaging tracer, not a therapy. Gozellix is a "kit" that hospitals use to prepare a radioactive contrast agent: the molecule gozetotide (PSMA-11) is tagged with radioactive gallium-68. Once injected, it binds to PSMA — a protein found in large amounts on prostate cancer cells — so the cancer lights up on a PET scan, helping doctors locate, stage, and manage prostate cancer. The kit format lets hospitals radiolabel it on-site, versus Telix's first-generation Illuccix, which ships as pre-made doses of the same tracer.
Trial Status
FDA approved the New Drug Application for Gozellix on March 21, 2025; commercial US launch followed in June 2025, with CMS reimbursement supporting uptake in Q4 2025. Gozellix is also included in Telix's BiPASS Phase 3 study (MRI combined with PSMA-PET), a distant readout. No pending regulatory decision for Gozellix itself.
The Two-Sided Case
Upcoming Catalysts
- No Gozellix-specific dated binary in the next ~12 months; watch instead quarterly revenue/volume disclosures (Q2 2026 results released Aug 20, 2026) and FY2026 guidance tracking (~US$950-970M revenue plus US$40M Regeneron other income)
- Market-share updates for the Illuccix/Gozellix two-product strategy vs. PYLARIFY
- Progress of Telix's BiPASS Phase 3 study (MRI + PSMA-PET using Illuccix/Gozellix) — a distant readout
- Telix pipeline catalysts (e.g., ProstACT Global Phase 3 TLX591-Tx therapy data) that move the stock more than Gozellix
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Telix Pharmaceuticals Limited PRESS-RELEASE TLX ·Originating report